Download PDF
Thromb Haemost 2025; 125(03): 189-193
DOI: 10.1055/a-2508-5708
Invited Clinical Focus

A European-Multicenter Network for the Implementation of Artificial Intelligence to Manage Complexity and Comorbidities of Atrial Fibrillation Patients: The ARISTOTELES Consortium

Giuseppe Boriani
1   Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
,
Davide Antonio Mei
1   Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
2   Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
3   Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
,
Gregory Y.H. Lip 
3   Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
4   Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
5   Medical University of Bialystok, Bialystok, Poland
,
on behalf of the ARISTOTELES consortium › Author Affiliations Funding European Commission, HORIZON EUROPE Framework Programme, HORIZON EUROPE Innovative Europe, HORIZON EUROPE European Innovation Council 101080189.
› Further Information
Also available at
   Permissions and Reprints

Introduction

Atrial fibrillation (AF) is the most common arrhythmia worldwide, contributing significantly to morbidity, healthcare costs, and resource utilization.[1] Patients with AF face a higher mortality and morbidity from stroke, heart failure, dementia, and hospitalizations.[1] Oral anticoagulants (OACs) are the cornerstone of AF management, as they substantially reduce the risk of stroke and mortality.[2] Nevertheless, some residual risk still remains despite anticoagulation, with most AF-related mortality linked to cardiovascular causes and comorbidities rather than stroke alone.[2] [3]

AF is not a yes/no homogeneous diagnosis. AF patients are often elderly, multimorbid, and frail, with associated polypharmacy, leading to “clinically complex” phenotypes or clusters. As comorbidities often cluster in different patterns, these impact on the risk of adverse outcomes and management. In the prospective GLORIA-AF registry of AF patients, the presence of clinical complexity was associated with lower odds of being prescribed with OAC (odds ratio [OR] 0.50, 95% confidence interval [CI] 0.44–0.57), higher OAC discontinuation, and with a higher risk of adverse events (hazard ratio [HR] 1.63, 95% CI 1.43–1.86).[4] Indeed, “high clinical complexity” patients defined using latent class analysis constituted 6.6% of AF patients, and was associated with higher hazards of experiencing the primary composite outcome of all-cause death and major adverse cardiovascular events (HR 1.47, 95% 1.24–1.75).[5] Comorbidities and polypharmacy have an important influence on decision-making, by conditioning either lack of prescription of OAC in patients at risk or inappropriate dosing.[6] [7] [8]

Recognizing that AF management is more than simply OAC alone, and requires a holistic and integrated care approach, contemporary guidelines globally on AF management have promoted this concept, based on the Atrial fibrillation Better Care (ABC) pathway, emphasizing Anticoagulation, Better symptom management with rate or rhythm control, and Comorbidity/lifestyle management.[9] [10] [11] The ABC pathway is well supported by clinical trial and real-world evidence,[11] whereby adherence to the ABC pathway is associated with a reduction in all-cause and cardiovascular mortality, stroke, and bleeding.[12] [13] Despite this, adherence to ABC-based management remains low, whereby a meta-analysis of 14 studies revealed that only 21% (95% CI 13–34%) of AF patients were managed in accordance with the ABC pathway.[12] This perhaps highlights a critical gap in the implementation of comprehensive evidence-based care strategies. Of note, the “ABC” acronym has been modified in US guidelines (as “SOS,” i.e., Stroke, Other Comorbidities, Rate or Rhythm control)[14] and the 2024 ESC guidelines (as “CARE,” i.e., Comorbidities, Avoid stroke, Rate or rhythm control, Evaluation),[15] although these new acronyms are untested in clinical trials.[11]

* The members of the ARISTOTELES consortium are mentioned in [Supplementary Appendix] (available in the online version).


Supplementary Material



Publication History

Received: 04 December 2024

Accepted: 27 December 2024

Article published online:
20 January 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Linz D, Gawalko M, Betz K. et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur 2024; 37: 100786
    CrossrefPubMedSearch in Google Scholar
  • 2 Lip GYH, Proietti M, Potpara T. et al. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace 2023; 25 (09) euad226
    CrossrefPubMedSearch in Google Scholar
  • 3 Ishiguchi H, Abdul-Rahim AH, Huang B. et al; GLORIA-AF Investigators. Residual risks of thrombotic complications in anticoagulated patients with atrial fibrillation: a cluster analysis approach from the GLORIA-AF Registry. J Gen Intern Med 2024; . Epub ahead of print.
    CrossrefPubMedSearch in Google Scholar
  • 4 Romiti GF, Proietti M, Bonini N. et al; GLORIA-AF Investigators. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF Registry Phase II and III. Thromb Haemost 2022; 122 (12) 2030-2041
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Romiti GF, Corica B, Mei DA. et al; GLORIA-AF Investigators. Patterns of comorbidities in patients with atrial fibrillation and impact on management and long-term prognosis: an analysis from the Prospective Global GLORIA-AF Registry. BMC Med 2024; 22 (01) 151
    CrossrefPubMedSearch in Google Scholar
  • 6 Guenoun M, Cohen S, Villaceque M. et al. Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF. Europace 2023; 25 (10) euad302
    CrossrefPubMedSearch in Google Scholar
  • 7 Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2024; 124 (02) 135-148
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Zheng Y, Li S, Liu X, Lip GYH, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thromb Haemost 2023; . Epub ahead of print.
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Wang Y, Guo Y, Qin M. et al; Expert Reviewers. 2024 Chinese expert consensus guidelines on the diagnosis and treatment of atrial fibrillation in the elderly, endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): executive summary. Thromb Haemost 2024; 124 (10) 897-911
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Chao TF, Joung B, Takahashi Y. et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Potpara T, Romiti GF, Sohns C. The 2024 European Society of Cardiology Guidelines for diagnosis and management of atrial fibrillation: a viewpoint from a practicing clinician's perspective. Thromb Haemost 2024; 124 (12) 1087-1094
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the “Atrial Fibrillation Better Care” pathway in patients with atrial fibrillation: impact on clinical outcomes—a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Treewaree S, Lip GYH, Krittayaphong R. Non-vitamin K antagonist oral anticoagulant, warfarin, and ABC pathway adherence on hierarchical outcomes: Win Ratio analysis of the COOL-AF Registry. Thromb Haemost 2024; 124 (01) 69-79
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Joglar JA, Chung MK, Armbruster AL. et al; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2024; 149 (01) e1-e156
    CrossrefPubMedSearch in Google Scholar
  • 15 Van Gelder IC, Rienstra M, Bunting KV. et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45 (36) 3314-3414
    CrossrefPubMedSearch in Google Scholar
  • 16 Hygrell T, Viberg F, Dahlberg E. et al. An artificial intelligence-based model for prediction of atrial fibrillation from single-lead sinus rhythm electrocardiograms facilitating screening. Europace 2023; 25 (04) 1332-1338
    CrossrefPubMedSearch in Google Scholar
  • 17 Svennberg E, Caiani EG, Bruining N. et al. The digital journey: 25 years of digital development in electrophysiology from an Europace perspective. Europace 2023; 25 (08) euad176
    CrossrefPubMedSearch in Google Scholar
  • 18 Olier I, Ortega-Martorell S, Pieroni M, Lip GYH. How machine learning is impacting research in atrial fibrillation: implications for risk prediction and future management. Cardiovasc Res 2021; 117 (07) 1700-1717
    CrossrefPubMedSearch in Google Scholar
  • 19 Ortega-Martorell S, Olier I, Ohlsson M, Lip GYH, Consortium T. TARGET Consortium. TARGET: a major European project aiming to advance the personalised management of atrial fibrillation-related stroke via the development of health virtual twins technology and Artificial Intelligence. Thromb Haemost 2025; 125 (01) 7-11
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Krittayaphong R, Winijkul A, Methavigul K, Chichareon P, Lip GYH. Clinical outcomes of patients with atrial fibrillation in relation to multimorbidity status changes over time and the impact of ABC pathway compliance: a nationwide cohort study. J Thromb Thrombolysis 2024; . Epub ahead of print.
    CrossrefPubMedSearch in Google Scholar
  • 21 Imberti JF, Bonini N, Tosetti A. et al. Atrial high-rate episodes detected by cardiac implantable electronic devices: dynamic changes in episodes and predictors of incident atrial fibrillation. Biology (Basel) 2022; 11 (03) 443
    PubMedSearch in Google Scholar
  • 22 Krittayaphong R, Chichareon P, Methavigul K, Treewaree S, Lip GYH. Relation of changes in ABC pathway compliance status to clinical outcomes in patients with atrial fibrillation: a report from the COOL-AF registry. Eur Heart J Qual Care Clin Outcomes 2024; qcae039. Epub ahead of print.
    CrossrefPubMedSearch in Google Scholar
  • 23 Zhao Y, Cao LY, Zhao YX. et al. Harnessing risk assessment for thrombosis and bleeding to optimize anticoagulation strategy in nonvalvular atrial fibrillation. Thromb Haemost 2024; . Epub ahead of print.
    Thieme ConnectPubMedSearch in Google Scholar
  • 24 Vitolo M, Proietti M, Imberti JF. et al. Factors associated with progression of atrial fibrillation and impact on all-cause mortality in a cohort of European patients. J Clin Med 2023; 12 (03) 768
    CrossrefPubMedSearch in Google Scholar
  • 25 Boriani G, Bonini N, Vitolo M. et al. Asymptomatic vs. symptomatic atrial fibrillation: clinical outcomes in heart failure patients. Eur J Intern Med 2024; 119: 53-63
    CrossrefPubMedSearch in Google Scholar
  • 26 Ding WY, Potpara TS, Blomström-Lundqvist C. et al; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF long-term general registry. Eur J Clin Invest 2022; 52 (06) e13745
    CrossrefPubMedSearch in Google Scholar
  • 27 Toprak B, Brandt S, Brederecke J. et al. Exploring the incremental utility of circulating biomarkers for robust risk prediction of incident atrial fibrillation in European cohorts using regressions and modern machine learning methods. Europace 2023; 25 (03) 812-819
    CrossrefPubMedSearch in Google Scholar
  • 28 Imberti JF, Mei DA, Vitolo M. et al. Comparing atrial fibrillation guidelines: focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. Eur J Intern Med 2022; 101: 1-7
    CrossrefPubMedSearch in Google Scholar
  • 29 Boriani G, Venturelli A, Imberti JF, Bonini N, Mei DA, Vitolo M. Comparative analysis of level of evidence and class of recommendation for 50 clinical practice guidelines released by the European Society of Cardiology from 2011 to 2022. Eur J Intern Med 2023; 114: 1-14
    CrossrefPubMedSearch in Google Scholar
  • 30 Lip GYH, Teppo K, Nielsen PB. CHA2DS2-VASc or a non-sex score (CHA2DS2-VA) for stroke risk prediction in atrial fibrillation: contemporary insights and clinical implications. Eur Heart J 2024; 45 (36) 3718-3720
    CrossrefPubMedSearch in Google Scholar